Fundamental Analysis of MEREO BIOPHARMA GROUP PL-ADR(NASDAQ:MREO) stock

Fundamental Rating

MREO gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 568 industry peers in the Biotechnology industry. While MREO has a great health rating, there are worries on its profitability. While showing a medium growth rate, MREO is valued expensive at the moment.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year MREO has reported negative net income.

In the past 5 years MREO reported 4 times negative net income.

In the past 5 years MREO always reported negative operating cash flow.

1.2 Ratios

The Return On Assets of MREO (-74.00%) is worse than 67.61% of its industry peers.

The Return On Equity of MREO (-90.54%) is comparable to the rest of the industry.

		Industry Rank	Sector Rank
ROA	-74%
ROE	-90.54%
ROIC	N/A

ROA(3y)-25.3%

ROA(5y)-75.27%

ROE(3y)-33.51%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

MREO has a better Gross Margin (74.26%) than 84.96% of its industry peers.

The Profit Margin and Operating Margin are not available for MREO so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	74.26%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

MREO does not have a ROIC to compare to the WACC, probably because it is not profitable.

The number of shares outstanding for MREO has been increased compared to 1 year ago.

MREO has more shares outstanding than it did 5 years ago.

MREO has a better debt/assets ratio than last year.

2.2 Solvency

An Altman-Z score of 10.39 indicates that MREO is not in any danger for bankruptcy at the moment.

With an excellent Altman-Z score value of 10.39, MREO belongs to the best of the industry, outperforming 87.08% of the companies in the same industry.

MREO has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Altman-Z	10.39

ROIC/WACCN/A

WACC8.8%

2.3 Liquidity

MREO has a Current Ratio of 6.10. This indicates that MREO is financially healthy and has no problem in meeting its short term obligations.

The Current ratio of MREO (6.10) is better than 61.59% of its industry peers.

A Quick Ratio of 6.10 indicates that MREO has no problem at all paying its short term obligations.

MREO has a better Quick ratio (6.10) than 62.12% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	6.1
Quick Ratio	6.1

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

MREO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 25.53%, which is quite impressive.

EPS 1Y (TTM)25.53%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, MREO will show a very strong growth in Earnings Per Share. The EPS will grow by 31.10% on average per year.

MREO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 87.41% yearly.

EPS Next Y63.3%

EPS Next 2Y-154.27%

EPS Next 3Y17.72%

EPS Next 5Y31.1%

Revenue Next Year43.85%

Revenue Next 2Y25.47%

Revenue Next 3Y104.4%

Revenue Next 5Y87.41%

3.3 Evolution

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for MREO. In the last year negative earnings were reported.

Also next year MREO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

A more expensive valuation may be justified as MREO's earnings are expected to grow with 17.72% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y-154.27%

EPS Next 3Y17.72%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for MREO!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

MEREO BIOPHARMA GROUP PL-ADR

NASDAQ:MREO (12/20/2024, 8:25:30 PM)

After market: 3.35 0 (0%)

3.35

+0.06 (+1.82%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)11-12 2024-11-12/bmo

Earnings (Next)N/A N/A

Inst Owners68.27%

Inst Owner Change5.68%

Ins Owners0.83%

Ins Owner Change47.29%

Market Cap515.41M

Analysts87.27

Price Target7.34 (119.1%)

Short Float %4.48%

Short Ratio8.72

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)0

Avg EPS beat(2)-668.13%

Min EPS beat(2)-886.64%

Max EPS beat(2)-449.62%

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)-62.49%

EPS NQ rev (3m)-62.49%

EPS NY rev (1m)27.42%

EPS NY rev (3m)27.42%

Revenue NQ rev (1m)-56.58%

Revenue NQ rev (3m)-56.58%

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	51.54
P/FCF	N/A
P/OCF	N/A
P/B	7.11
P/tB	7.18
EV/EBITDA	N/A

EPS(TTM)-0.47

EYN/A

EPS(NY)-0.28

Fwd EYN/A

FCF(TTM)N/A

FCFYN/A

OCF(TTM)N/A

OCFYN/A

SpS0.06

BVpS0.47

TBVpS0.47

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-74%
ROE	-90.54%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	74.26%
FCFM	N/A

ROA(3y)-25.3%

ROA(5y)-75.27%

ROE(3y)-33.51%

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-ScoreN/A

Asset Turnover0.11

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	6.1
Quick Ratio	6.1
Altman-Z	10.39

F-ScoreN/A

WACC8.8%

ROIC/WACCN/A

Cap/Depr(3y)28.58%

Cap/Depr(5y)17.65%

Cap/Sales(3y)N/A

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)25.53%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%N/A

EPS Next Y63.3%

EPS Next 2Y-154.27%

EPS Next 3Y17.72%

EPS Next 5Y31.1%

Revenue 1Y (TTM)N/A

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%N/A

Revenue Next Year43.85%

Revenue Next 2Y25.47%

Revenue Next 3Y104.4%

Revenue Next 5Y87.41%

EBIT growth 1Y34.78%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y54.6%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y54.59%

OCF growth 3YN/A

OCF growth 5YN/A

MEREO BIOPHARMA GROUP PL-ADR (MREO)

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens